Infectious disease Archives

News and Trends 16 Dec 2022

Providence Therapeutics’ mRNA rabies vaccine hits milestone

Providence Therapeutics Holdings Inc. says its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines utilizing Providence’s clinically validated mRNA technology platform. “We are pleased to demonstrate that Providence’s mRNA technology supports development of additional products that fight a number of […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

MinervaX raises €72M to develop Group B Streptococcus vaccine

MinervaX ApS, a privately held Danish biotech company developing a novel vaccine against Group B Streptococcus (GBS), has completed a €72 million ($76.5 million) financing round. The equity financing of €22 million ($23.4 million) was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

In Depth 1 Dec 2022

Is an HIV Cure Possible? The Future of HIV Therapy

HIV research has come a long way since the virus was discovered in the 1980s. Antiretroviral therapy was a major milestone that has changed the lives of millions; the goal now is to find an HIV cure. Back in 2008, Timothy Ray Brown was the first person to be cured of HIV. Known as the […]

December 1, 2022 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Nov 2022

Replay receives $1.5M grant for hypoimmunogenic technology platform

Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

Impacting vaccine development: COVID-19 and its implications for the future of vaccines

The development of COVID-19 vaccines was an unprecedented achievement at a time of urgent medical need. We explore the novel technology platforms that went into their development and consider their long-term impact on vaccine research. Ever since the first vaccine against smallpox in the late 1700s, vaccines have gained a reputation as a critical tool […]

November 3, 2022 - 8 minutesmins - By Sudha Sundaram

Interview 28 Oct 2022

Migraines: a new vaccine frontier beyond infectious diseases

By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S. company Vaxxinity aims to open a new frontier for vaccines in an effort to reach all patient populations, regardless of location or income. Migraine causes severe headaches that are characterized by throbbing pain and associated symptoms such as sensitivity to […]

October 28, 2022 - 7 minutesmins - By Omnia Ibrahim

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

Best in Biotech 28 Sep 2022

The 5 hottest private biotechs in South Africa

Biotechnology companies are sprouting in South Africa’s maturing life sciences industry. We’ve listed five private biotech companies that have turned heads in the last few years. South Africa boasts the second biggest economy in Africa after Nigeria. While famous for its rich mineral wealth, South Africa’s economy has diversified widely in the past decades to […]

September 28, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 21 Sep 2022

Poolbeg to investigate melioidosis vaccine candidate

Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Aldatu gets grant to develop Crimean Congo hemorrhagic fever test

U.S. biotech company Aldatu Biosciences has been awarded a $3 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the advancement of the company’s proprietary PANDAA technology platform and its specific application to the […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Proxidrugs: a new tool to fight pathogens?

Scientists at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany are working with partners to develop a new drug class. Proxidrugs (or proximity-inducing drugs) utilize cells’ waste disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in […]

September 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine

Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […]

August 29, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us